JP5570974B2 - 一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体 - Google Patents

一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体 Download PDF

Info

Publication number
JP5570974B2
JP5570974B2 JP2010509681A JP2010509681A JP5570974B2 JP 5570974 B2 JP5570974 B2 JP 5570974B2 JP 2010509681 A JP2010509681 A JP 2010509681A JP 2010509681 A JP2010509681 A JP 2010509681A JP 5570974 B2 JP5570974 B2 JP 5570974B2
Authority
JP
Japan
Prior art keywords
human
region
replaced
ala
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010509681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527622A (ja
JP2010527622A5 (cg-RX-API-DMAC7.html
Inventor
ジェニン スヒュールマン
トム ビンク
デ ウィンケル ヤン バン
アラン フランク ラブレイン
ポール パーレン
ウィレム カレル ブレーカー
フランク ビュースケンス
べーケル パトリック バン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2010527622A publication Critical patent/JP2010527622A/ja
Publication of JP2010527622A5 publication Critical patent/JP2010527622A5/ja
Application granted granted Critical
Publication of JP5570974B2 publication Critical patent/JP5570974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
JP2010509681A 2007-05-31 2008-05-30 一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体 Active JP5570974B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700795 2007-05-31
DKPA200700795 2007-05-31
PCT/DK2008/050127 WO2008145140A2 (en) 2007-05-31 2008-05-30 Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals

Publications (3)

Publication Number Publication Date
JP2010527622A JP2010527622A (ja) 2010-08-19
JP2010527622A5 JP2010527622A5 (cg-RX-API-DMAC7.html) 2011-07-14
JP5570974B2 true JP5570974B2 (ja) 2014-08-13

Family

ID=39671787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509681A Active JP5570974B2 (ja) 2007-05-31 2008-05-30 一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体

Country Status (6)

Country Link
US (2) US9322035B2 (cg-RX-API-DMAC7.html)
EP (2) EP2167669A2 (cg-RX-API-DMAC7.html)
JP (1) JP5570974B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008255350B2 (cg-RX-API-DMAC7.html)
CA (1) CA2689695A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008145140A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107581155A (zh) * 2017-11-08 2018-01-16 成都新柯力化工科技有限公司 一种用于母猪繁殖的led灯及利用该led灯促进母猪繁殖的方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
EP2167669A2 (en) 2007-05-31 2010-03-31 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
JP5746040B2 (ja) * 2008-12-03 2015-07-08 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
EP2638066A4 (en) * 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
GB2496375A (en) * 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US10865253B2 (en) 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
US10544220B2 (en) * 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN114276433A (zh) * 2020-04-01 2022-04-05 百奥赛图(北京)医药科技股份有限公司 Cd38基因人源化的非人动物及其构建方法和应用
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
MXPA03011365A (es) 2001-06-13 2005-03-07 Genmab As Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
WO2003000176A2 (en) 2001-06-20 2003-01-03 Molecular Staging, Inc. Conjugates of reduced antibodies and biomolecules
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
WO2004026427A2 (en) * 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
DK1562972T3 (da) * 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CN103709250B (zh) 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
US7608429B2 (en) * 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004045512A2 (en) * 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
DK1718677T3 (da) 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
RU2007108538A (ru) 2004-08-11 2008-09-20 Трабьон Фармасьютикалз, Инк. (Us) Слитые со связывающим доменом белки
CA2580981C (en) * 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
NZ597168A (en) * 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP1973576B1 (en) * 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1960431B1 (en) * 2005-12-15 2014-10-01 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
US20110045007A1 (en) * 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
EP4119579A1 (en) * 2007-05-31 2023-01-18 Genmab A/S Stable igg4 antibodies
WO2008145141A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2167669A2 (en) 2007-05-31 2010-03-31 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
JP5746040B2 (ja) 2008-12-03 2015-07-08 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107581155A (zh) * 2017-11-08 2018-01-16 成都新柯力化工科技有限公司 一种用于母猪繁殖的led灯及利用该led灯促进母猪繁殖的方法

Also Published As

Publication number Publication date
JP2010527622A (ja) 2010-08-19
WO2008145140A3 (en) 2009-01-29
CA2689695A1 (en) 2008-12-04
WO2008145140A2 (en) 2008-12-04
AU2008255350A1 (en) 2008-12-04
EP2615175A1 (en) 2013-07-17
US20100306867A1 (en) 2010-12-02
AU2008255350B2 (en) 2014-07-10
US9322035B2 (en) 2016-04-26
US20170037138A1 (en) 2017-02-09
US10351629B2 (en) 2019-07-16
EP2615175B1 (en) 2018-08-08
EP2167669A2 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
JP5570974B2 (ja) 一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体
US20220396629A1 (en) Recombinant monovalent antibodies and methods for production thereof
JP5511654B2 (ja) 分子操作により得られた組換え非グリコシル化一価半抗体
US20100291023A1 (en) Method for extending the half-life of exogenous or endogenous soluble molecules
US20100255012A1 (en) Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
JP4308470B2 (ja) 抗Ｆｃ受容体結合薬からなる治療用化合物
CN111183153A (zh) Cd3/cd33双特异性结合分子
JP2024512035A (ja) Ｃｄ２２及びｃｄ７９ｂを標的とする抗体
AU2017200199B2 (en) Recombinant monovalent antibodies and methods for production thereof
CN101370526B (zh) 重组单价抗体及其制备方法
AU2013216644A1 (en) Recombinant monovalent antibodies and methods for production thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140625

R150 Certificate of patent or registration of utility model

Ref document number: 5570974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250